ARMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Armata Pharmaceuticals Inc (ARMP) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential due to its innovative phage therapies and upcoming Phase 3 trials, the recent financial performance shows significant revenue decline and high net losses. Additionally, the technical indicators are mixed, and no significant trading signals or positive news catalysts are present. It is better to wait for further developments or a more favorable entry point.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 44.272, showing no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the price is below the pivot level of 11.077, with key support at 10.309. Overall, the technicals are mixed.
Analyst upgrades with a price target increase to $15 and the FDA's Qualified Infectious Disease Product designation for AP-SA02, which strengthens the regulatory framework for future trials.
Significant revenue drop (-61.02% YoY) in Q3 2025, high net losses (-$26.68M), and no recent news or significant trading activity from hedge funds, insiders, or Congress. Additionally, the market sentiment is bearish with SP500 down -1.52%.
In Q3 2025, revenue dropped significantly by 61.02% YoY to $1.16M. Net income improved to -$26.68M (up 386.68% YoY), and EPS increased to -0.74 (up 393.33% YoY). Gross margin remained at 100%. Despite EPS improvement, the financials reflect a struggling company with declining revenue.
Analysts are positive with a Buy rating and a price target of $15, citing the company's innovative phage therapies and in-house manufacturing capabilities. However, the catalysts are long-term, with Phase 3 trials expected in the second half of 2026.
